Skip to main content
Mayinglong Pharmaceutical Group Co.,Ltd logo

Mayinglong Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 600993 ISIN · CNE000001HN2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 931 across all filing types
Latest filing 2015-11-11 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600993

About Mayinglong Pharmaceutical Group Co.,Ltd

https://www.mayinglong.cn/

Mayinglong Pharmaceutical Group Co.,Ltd. is a long-established enterprise specializing in the research, development, and production of Traditional Chinese Medicine (TCM). Founded in 1582, the company is widely recognized for its expertise in proctology, maintaining a dominant market position with its signature hemorrhoid ointments and suppositories. Its product portfolio also includes ophthalmic preparations, dermatological treatments, and gastrointestinal medicines. The company integrates traditional medicinal formulas with modern manufacturing technologies to provide healthcare solutions. Beyond pharmaceuticals, Mayinglong has expanded into healthcare services, including specialized hospitals and personal care products, focusing on the integration of clinical treatment and health management.

Recent filings

Filing Released Lang Actions
关于获得《药品GMP证书》的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement from a company about receiving a new GMP (Good Manufacturing Practice) certificate issued by a regulatory authority (湖北省食品药品监督管理局). It is not a financial report, audit, or management change notice. It is a regulatory announcement about certification, which does not fit into financial or governance report categories. The document length is short (551 characters) and it is an announcement of a certificate received, not a detailed report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other categories.
2015-11-11 Chinese
关于药品生产许可证变更的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (401 characters) from a company's board about a change in the drug production license issued by a regulatory authority. It does not contain financial data, management changes, or detailed reports. It is an official announcement regarding a regulatory approval or license change. This fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2015-11-04 Chinese
2015年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2015 年第三季度报告' which translates to '2015 Third Quarter Report'. It contains detailed financial data including balance sheet items, profit and loss items, cash flow items, and shareholder information for the third quarter of 2015. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for a period shorter than a full fiscal year. It is not an announcement or a brief summary but a full report with substantive financial data. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2015-10-25 Chinese
关于股东股权解除质押的公告
Major Shareholding Notification Classification · 95% confidence The document is a short announcement regarding the release of pledged shares by a major shareholder. It includes specific share counts, percentages of total share capital, and dates related to the pledge release. There is no financial report, earnings data, or management discussion. The content fits the description of a Major Shareholding Notification, as it informs about changes in significant share ownership levels (release of pledged shares by a major shareholder). The document length is short and focused on shareholding changes, not a full report or announcement of a report publication.
2015-10-20 Chinese
关于股东股权质押的公告
Major Shareholding Notification Classification · 95% confidence The document is a short announcement regarding the pledge of shares by a major shareholder (China Baoan Group) of the company Mayinglong Pharmaceutical Group Co., Ltd. It details the number of shares pledged, the pledgee (China Construction Bank), and the percentage of total shares pledged. There is no financial report, audit, or management discussion. The content fits the definition of a Major Shareholding Notification, as it informs about changes in significant share ownership levels or encumbrances on shares.
2015-09-23 Chinese
2015年半年度报告摘要
Interim / Quarterly Report Classification · 100% confidence The document is titled as a '2015 年半年度报告摘要' which translates to '2015 Half-Year Report Summary'. It contains detailed financial data for the first half of 2015, including revenue, profit, cash flow, segment analysis, shareholder information, and management discussion and analysis. The presence of comprehensive financial statements and substantive financial data for a period shorter than a full fiscal year indicates this is an Interim / Quarterly Report. The document length is over 11,000 characters, so it is not a mere announcement or summary notice. There is no indication that this is an Annual Report, Audit Report, or other types of filings. Therefore, the classification is Interim / Quarterly Report (IR). H1 2015
2015-08-21 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.